Cartesian Therapeutics, Inc. is a late clinical-stage biotechnology company focused on developing cell therapy treatments for autoimmune diseases.
The company uses its proprietary mRNA based technology to modify patients’ own T cells ex vivo, enabling the expression of chimeric antigen receptors without integrating genetic material into the host genome.
Because the mRNA transcript degrades naturally, the therapy avoids permanent genomic changes and reduces the risk of…
Cartesian Therapeutics, Inc. is a late clinical-stage biotechnology company focused on developing cell therapy treatments for autoimmune diseases. The company uses its proprietary mRNA based technology to modify patients’ own T cells ex vivo, enabling the expression of chimeric antigen receptors without integrating genetic material into the host genome. Because the mRNA transcript degrades naturally, the therapy avoids permanent genomic changes and reduces the risk of oncogenic transformation. This approach allows the product to be administered repeatedly in an outpatient setting without the need for preconditioning chemotherapy. Cartesian Therapeutics targets diseases such as myasthenia gravis, myositis, lupus and other autoimmune disorders where current standard of care relies on chronic immunosuppressant agents. The company’s manufacturing process is conducted in-house at its cGMP facility in Frederick Maryland, enabling patient specific production and release of product lots within approximately three weeks. As of December 31 2025, the lead candidate had been administered to more than one hundred patients in open label placebo controlled trials across multiple indications.
The company generates revenue primarily through licensing and collaboration agreements that provide upfront payments, milestone payments and royalty streams. Under the Biogen agreement, Cartesian Therapeutics holds a non exclusive worldwide license to certain patents covering mRNA engineered T cell technologies, with no obligation to pay fees or royalties to Biogen. The NCI agreement includes an upfront payment of one hundred thousand dollars, low five digit annual royalties, low single digit percentages on net sales and potential benchmark payments up to eight hundred thousand dollars. The Sobi agreement provides for possible milestone payments totaling up to six hundred thirty million dollars and tiered royalties ranging from low double digits to high teens on net sales of the licensed product. Additional revenue may be derived from research collaborations, government contracts and grant funding that support the advancement of the mRNA based CAR T platform. To date, the company has not reported any product sales revenue as its candidates remain in clinical development.
Within the emerging field of mRNA based cell therapy for autoimmune indications, Cartesian Therapeutics positions itself as a pioneer that avoids the genomic integration and cytokine release risks associated with conventional DNA engineered CAR T products. Clinical data show that its lead candidate has been well tolerated with no reports of cytokine release syndrome, neurotoxicity or grade three or higher adverse events in treated patients. The therapy has demonstrated durable clinical benefit, with improvements in disease activity scores persisting beyond twelve months in a subset of participants. Regulatory recognition includes orphan drug designation, regenerative medicine advanced therapy designation and rare pediatric disease designation from the U. S. Food and Drug Administration for its lead candidate in myasthenia gravis. Competitors in the autoimmune space include established biopharmaceutical companies such as Argenx, Alexion, Johnson & Johnson, AstraZeneca and emerging cell therapy firms like Kyverna Therapeutics and Cabaletta Bio that are pursuing alternative immunomodulatory strategies. Cartesian Therapeutics differentiates itself through its manufacturing control, outpatient administration model and the ability to redose patients without chemotherapy.
Cartesian Therapeutics serves patients suffering from severe autoimmune diseases, including individuals with acetylcholine antibody positive myasthenia gravis, refractory dermatomyositis, antisynthetase syndrome and juvenile dermatomyositis. The company’s therapies are intended for administration by healthcare providers in outpatient infusion centers, hospitals and specialty clinics that focus on immunology and neurology. As of the latest filings, over one hundred patients have received the lead candidate in clinical trials, providing a foundation for commercial scale up. The company also engages with patient advocacy groups and clinical investigators to support trial enrollment and disease awareness.